EXICURE HITRON (019490) AI Stock Analysis

Top Page

EXICURE HITRON

(Korea Exchange:019490)

Select Model

Rating:40Underperform

Action:initiatedcoverage

Date:10/28/26

The score is driven primarily by very weak financial performance—persistent losses, volatile/declining revenue (notably the 2025 drop), and ongoing negative operating/free cash flow. With technical indicators and earnings-call insights unavailable and valuation signals constrained by a negative P/E, there are limited offsets to the elevated fundamental risk.

Positive Factors

Moderate latest leverageThe latest balance-sheet leverage is more moderate than in prior peak-leverage years, providing some relative financial stability. This may preserve more flexibility for operations and development than the company had during periods of extreme leverage, although continued losses remain a constraint.

Negative Factors

Persistent unprofitabilityConsistently negative gross, operating, and net profit show that the business has not yet demonstrated a sustainable economic model. Continued negative margins can consume capital, limit reinvestment capacity, and make future growth dependent on funding rather than internally generated earnings.

EXICURE HITRON Business Overview & Revenue Model

Company Description

Exicure Hitron Inc., a South Korean company founded in 1986 and based in Anseong, specializes in the global manufacturing and distribution of security and surveillance equipment. Their extensive product line includes a variety of advanced network cam...

EXICURE HITRON Financial Statement Overview

Summary

Financial performance is very weak: profitability is consistently negative with a sharp revenue contraction in 2025, and cash flow remains negative in 2023–2025 (renewed cash burn). The balance sheet is somewhat improved versus prior peak-leverage years, but leverage volatility and strongly negative returns keep overall financial risk high.

Income Statement

8Very Negative

Balance Sheet

32Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.84B	5.30B	6.58B	5.50B	10.77B	27.48B
Gross Profit	-625.50M	-879.30M	-1.66B	-558.81M	-2.70B	-6.56B
EBITDA	-4.58B	-3.71B	-60.56B	-5.59B	-7.11B	-17.70B
Net Income	-25.02B	-28.10B	-59.32B	-7.04B	-9.29B	-12.96B
Balance Sheet
Total Assets	40.31B	42.29B	79.52B	27.56B	16.84B	47.44B
Cash, Cash Equivalents and Short-Term Investments	1.93B	3.70B	34.86B	16.53B	492.46M	2.43B
Total Debt	5.24B	7.88B	26.36B	13.41B	906.71M	12.34B
Total Liabilities	27.61B	26.58B	45.63B	20.49B	3.86B	26.72B
Stockholders Equity	10.76B	12.37B	26.43B	7.07B	12.98B	20.72B
Cash Flow
Free Cash Flow	-12.36B	-16.82B	-12.52B	-7.07B	9.19B	-17.68B
Operating Cash Flow	-11.59B	-15.50B	-9.93B	-6.60B	9.51B	-17.41B
Investing Cash Flow	10.84B	6.07B	-6.02B	-3.67B	3.66B	33.86B
Financing Cash Flow	-14.48B	-14.17B	30.72B	26.36B	-15.03B	-17.96B

EXICURE HITRON Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:019490 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:019490	40Underperform	KRW 41.34B	-1.54	―	―	―	―

* General Sector Average

Performance Comparison

KR:019490 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:038070	Seoulin Bioscience Co.,Ltd.	3565.00	-2558.81	-41.78%
KR:086060	Gene Bio Tech Co., Ltd.	5030.00	1244.76	32.88%
KR:215380	WOOJUNG BIO, Inc.	2045.00	55.00	2.76%
KR:238120	Aligned Genetics, Inc.	2570.00	-675.00	-20.80%
KR:382150	Oncocross Co., Ltd.	2875.00	-5495.00	-65.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

EXICURE HITRON AI Stock Analysis